Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RIPK1 | Q13546 | 15/20 | 0.64 |
| ▸ | NPC1 | O15118 | 1/20 | 0.44 |
| ▸ | GSK3B | P49841 | 1/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19228506 | 0.83 | RIPK1 (0.53) | RIPK1NPC1GSK3BMEN1KMT2A | |
| SCHEMBL31249665 | 0.83 | RIPK1 (0.53) | RIPK1NPC1GSK3BMEN1KMT2A | |
| SCHEMBL29415677 | 0.83 | RIPK1 (0.53) | RIPK1NPC1GSK3BMEN1KMT2A | |
| SCHEMBL19228402 | 0.83 | RIPK1 (0.53) | RIPK1NPC1GSK3BMEN1KMT2A | |
| SCHEMBL19207863 | 0.81 | RIPK1 (0.72) | RIPK1 | |
| SCHEMBL19255778 | 0.81 | RIPK1 (0.72) | RIPK1 | |
| SCHEMBL19207459 | 0.81 | RIPK1 (0.72) | RIPK1 | |
| SCHEMBL29415720 | 0.81 | RIPK1 (0.72) | RIPK1 | |
| SCHEMBL15564765 | 0.80 | PARP1 (0.55) | RIPK1MEN1KMT2A | |
| SCHEMBL15564861 | 0.80 | PARP1 (0.55) | RIPK1MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3781571-B1 | N-[4-OXO-2,3-DIHYDRO-PYRIDO[3,2-B][1,4]OXAZEPIN-3-YL]-5,6-DIHYDRO-4H-PYRROLO[1,2-B]PYRAZOLE-2-CARBOXAMIDE DERIVATIVES AND RELATED COMPOUNDS AS RIP1 KINASE INHIBITORS FOR TREATING E.G. IRRITABLE BOWEL SYNDROME (IBS) | HOFFMANN LA ROCHE (CH) | 2024-01-17 | — | — | EP | disclosed |
| US-20230043400-A1 | Compounds, Compositions and Methods | DENALI THERAPEUTICS INC. (US) | 2023-02-09 | — | — | US | disclosed |
| EP-3781571-A1 | N-[4-OXO-2,3-DIHYDRO-1,5-BENZOXAZEPIN-3-YL]-5,6-DIHYDRO-4H-PYRROLO[1,2-B]PYRAZOL E-2-CARBOXAMIDE DERIVATIVES AND RELATED COMPOUNDS AS RIP1 KINASE INHIBITORS FOR TREATING E.G. IRRITABLE BOWEL SYNDROME (IBS) | F. Hoffmann-La Roche AG (CH) | 2021-02-24 | — | — | EP | disclosed |
| US-20200317691-A1 | Compounds, Compositions and Methods | DENALI THERAPEUTICS INC. (US) | 2020-10-08 | — | — | US | disclosed |
| WO-2019204537-A1 | N-[4-OXO-2,3-DIHYDRO-1,5-BENZOXAZEPIN-3-YL]-5,6-DIHYDRO-4H-PYRROLO[1,2-B]PYRAZOL E-2-CARBOXAMIDE DERIVATIVES AND RELATED COMPOUNDS AS RIP1 KINASE INHIBITORS FOR TREATING E.G. IRRITABLE BOWEL SYNDROME (IBS) | GENENTECH, INC. (US) | 2019-10-24 | — | — | WO | disclosed |
| US-20190112318-A1 | COMPOUNDS, COMPOSITIONS AND METHODS | DENALI THERAPEUTICS INC. | 2019-04-18 | — | — | US | disclosed |
| EP-3414239-A2 | INHIBITORS OF RECEPTOR-INTERACTING PROTEIN KINASE 1 | Denali Therapeutics Inc. (US) | 2018-12-19 | — | — | EP | disclosed |
| WO-2017136727-A2 | COMPOUNDS, COMPOSITIONS AND METHODS | DENALI THERAPEUTICS INC. (US) | 2017-08-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200317691-A1 | Compounds, Compositions and Methods | PIK3CA, PLK1, PIK3CB | RIPK1 416/4885NPC1 1287/4885GSK3B 101/4885 |
| US-20230043400-A1 | Compounds, Compositions and Methods | PIK3CA, PLK1, PIK3CB | RIPK1 416/4885NPC1 1287/4885GSK3B 101/4885 |
| US-20190112318-A1 | COMPOUNDS, COMPOSITIONS AND METHODS | PIK3CA, PLK1, PIK3CB | RIPK1 416/4885NPC1 1287/4885GSK3B 101/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.